[BostonCard]

Minor detail on the Oxford/AZ vaccine, which is that it is based on a replication incompetent chimpanzee adenovirus, whereas the Russian and Chinese vaccines use an attenuated human adenovirus.

https://www.nature.com/articles/s41586-020-2798-3

Several replication-incompetent vector vaccine candidates against SARS-CoV-2 have progressed far in clinical development: results from NHP trials and/or clinical trials in humans have been reported for ChAdOx1 nCoV-19 (based on a chimpanzee AdV)47, by Janssen (using an AdV26-based vector)41 and by CanSino (AdV5)45,46; in addition, a candidate from the Gamaleya Research Institute (Ad5/Ad26)50 is in phase III clinical trials and another from ReiThera (gorilla AdV) is in phase I trials32 (Fig. 4, Tables 1, 2).

(CanSino is the Chinese vaccine, the Gamaleya Research Institute is the Russian one).


BC

[BostonCard]

Minor detail on the Oxford/AZ vaccine, which is that it is based on a replication incompetent chimpanzee adenovirus, whereas the Russian and Chinese vaccines use an attenuated human adenovirus.

https://www.nature.com/articles/s41586-020-2798-3

Several replication-incompetent vector vaccine candidates against SARS-CoV-2 have progressed far in clinical development: results from NHP trials and/or clinical trials in humans have been reported for ChAdOx1 nCoV-19 (based on a chimpanzee AdV)47, by Janssen (using an AdV26-based vector)41 and by CanSino (AdV5)45,46; in addition, a candidate from the Gamaleya Research Institute (Ad5/Ad26)50 is in phase III clinical trials and another from ReiThera (gorilla AdV) is in phase I trials32 (Fig. 4, Tables 1, 2).

(CanSino is the Chinese vaccine, the Gamaleya Research Institute is the Russian one).


BC